Vitality Watch

Dossier clinicaltrials trial early 04-sep-2026
Small or early-phase human trial or pilot study

Effects of Shanyu Pill in Older Adults With Sarcopenia

Key claim: A multicenter randomized double-blind placebo-controlled trial is testing whether 24 weeks of Shanyu Pill improves appendicular skeletal muscle mass, strength, physical performance, and cognition in older adults with sarcopenia.

Abstract

Sarcopenia is an age-related condition characterized by progressive loss of muscle mass, muscle strength, and physical function. It may also be associated with impaired cognitive function. Effective treatment options for sarcopenia remain limited.

This multicenter, randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the effects of Shanyu Pill in older adults with sarcopenia. A total of 192 participants are randomly assigned in a 1:1 ratio to receive either Shanyu Pill or placebo for 24 weeks. A long-term follow-up assessment is scheduled 2 years after completion of the 24-week intervention.

The primary outcome is the change in appendicular skeletal muscle mass index (ASMI) from baseline to week 24. Other assessments include muscle strength, physical performance, cognitive function, and traditional Chinese medicine syndrome severity assessed using the Spleen Qi Deficiency Syndrome Score. Musculoskeletal ultrasound, functional near-infrared spectroscopy, gut microbiota analysis, and untargeted metabolomics are also used in subsets of participants to explore potential mechanisms associated with the effects of Shanyu Pill, including possible interactions within the gut-muscle-brain axis.

Why this matters

Sarcopenia trials of traditional Chinese medicine formulas rarely reach multicenter double-blind placebo-controlled design, so this protocol raises the evidence ceiling for Shanyu Pill from mechanistic and clinical-use claims toward a testable outcome. The embedded gut–muscle–brain substudies also make it one of the few sarcopenia trials structurally set up to link a botanical intervention to microbiome and cognitive endpoints in the same cohort. Until the readout, the page remains a registered-trial marker, not an efficacy signal.

Source

Link

Briefing card

Effects of Shanyu Pill in Older Adults With Sarcopenia
Stage: trial early · clinicaltrials · 04-sep-2026

A multicenter randomized double-blind placebo-controlled trial is testing whether 24 weeks of Shanyu Pill improves appendicular skeletal muscle mass, strength, physical performance, and cognition in older adults with sarcopenia.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT05919368

build build 880 · 2bcef25 · 2026-11-18